Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel ...

The medication will be provided through PANTHERx Rare ... to lower the levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at high doses has been associated with ...

Neurocrine Biosciences, Inc. (NBIX) said that the U.S. Food and Drug Administration has approved CRENESSITY (crinecerfont) capsules ...

Neurocrine Biosciences stock jumped Monday after the company won FDA approval for the first new treatment for an adrenal disease in decade ...

Agents that directly lower ACTH secretion by a pituitary adenoma represent an attractive option for the treatment of Cushing's disease, as these drugs directly target the pathogenesis of disease.

The adrenal glands are stimulated by ACTH to release approximately 20 mg ... Patients are more likely to adhere to medication schedules if signs and symptoms are controlled and tolerated.

Atumelnant is a small molecule commercialized by Crinetics Pharmaceuticals, with a leading Phase II program in Congenital Adrenal Hyperplasia (Adrenogenital Syndrome).